Business
OWC Pharmaceutical Research Corp. Issues Chairman's Statement to Shareholders
OWC Pharmaceutical Research Corp. Issues Chairman's Statement to Shareholders.
About this update from Owc Pharmaceutical Research Corp
[{"type":"text","content":"\n\n\n\nOWC Pharmaceutical Research Corp. Issues Chairman's Statement to Shareholders\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nOWC Pharmaceutical Research Corp. Issues Chairman's Statement to Shareholders\nPR Newswire\nPETACH TIKVA, Israel, March 8, 2018\n\n\n\nPETACH TIKVA, Israel, March 8, 2018 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today issued a chairman's statement to shareholders.\n\n\nIn the light of recent events, and the numerous communications we have received from shareholders, I would like to address this statement to the Shareholders of OWCP (the \"Company\").\n\nThe Company is committed to building a leadership position in the medical cannabis market and to our mission of improving patients' lives through the development of new solutions, products and devices derived from and delivery mechanisms for the use of medical cannabis.\n\nWe have recruited a highly skilled management team with multi-year experience in medical cannabis, pharmaceutical development, corporate management and capital markets.\n\nAs we have stated in our 8-K filing of today, we are neither a party to the pending SEC action against a former adviser to the Company, nor is the Company alleged to have been a party to nor had any knowledge of the purported scheme by the former adviser, who is the subject of the SEC action.\n\nThe Company's management is committed to and focused on our development programs which are continuing as per plan. These include inter alia, our current safety trial for our cannabis cream; the approval processes to initiate a safety trial for our oral disintegrating tablet and additional pipeline projects.\n\nAs a management team, we are committed to building value for our shareholders though professional, ethical and strategic management of a technology platform that we believe will bring improved health and quality of life to millions of patients around the world. We have recently announced the addition of our ne...